Short Interest in Trinity Biotech plc (NASDAQ:TRIB) Surges by 63.5%
Trinity Biotech plc (NASDAQ:TRIB) has seen a substantial increase in short interest during May. As of May 31st, the short interest in Trinity Biotech totalled 12,100 shares, reflecting a significant 63.5% rise from the 7,400 shares recorded on May 15th. Based on an average daily trading volume of 23,700 shares, the short-interest ratio stands at 0.5 days. Approximately 0.2% of the stock's total shares are currently short sold.
Trinity Biotech Stock Declines 19.7%
NASDAQ:TRIB opened at $2.78 on Friday, marking a notable decline. The stock has experienced a 52-week low of $1.49 and a 52-week high of $5.50. Trinity Biotech's market capitalization is $21.19 million, with a PE ratio of -1.00 and a beta of 1.16. The stock’s 50-day average price is $1.87, while its 200-day moving average is $2.16.
Quarterly Financial Results
Trinity Biotech (NASDAQ:TRIB) recently reported its earnings results for the quarter on April 4th. The company announced an EPS of ($0.68) and generated $13.43 million in revenue during the quarter. Sell-side analysts predict that Trinity Biotech will post an earnings per share of -2.17 for the current fiscal year.
Analysts' Ratings
Separately, StockNews.com initiated coverage on Trinity Biotech, issuing a “buy” rating on the stock in a research report published on Tuesday.
Company Overview
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products targeting the clinical laboratory and point-of-care segments within the diagnostic market in the Americas and Ireland. The company's product portfolio includes clinical laboratory diagnostic tests and instruments, which detect infectious diseases such as syphilis, herpes, and SARS-CoV-2. The offerings also cover a wide array of viral pathogens including Epstein Barr, measles, mumps, rubella, and more. Additionally, Trinity Biotech provides in-vitro diagnostic testing for haemoglobin A1c, essential for diagnosing and monitoring diabetes.
Learn more about Trinity Biotech plc here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Readers are encouraged to conduct their own research or seek the guidance of a professional advisor.
